NAMSW
NewAmsterdam Pharma Company N.V. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.13
52W High
$29.99
52W Low
$6.30
50-Day MA
$21.26
200-Day MA
$19.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cardiometabolic diseases, with its lead asset designed to address dyslipidemia—a critical risk factor for cardiovascular conditions. The firm emphasizes a deep scientific approach and a well-structured R&D framework, which positions it favorably for potential regulatory approval and subsequent commercialization of its unique drug candidates. By targeting significant unmet medical needs, NewAmsterdam aims to improve patient outcomes while enhancing shareholder value, making it a noteworthy entity in the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $22.50M |
| Gross Profit (TTM) | $22.50M |
| EBITDA | $-225.46M |
| Operating Margin | -206188.00% |
| Return on Equity | -28.30% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.97 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | 0 |
| Float | $71.47M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
103.01%
HV 20-Day
85.42%
HV 30-Day
105.85%
HV 60-Day
95.49%
HV Rank
73.0%
Volatility is currently contracting
Data last updated: 4/9/2026